Results 101 to 110 of about 2,133 (164)

Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials. [PDF]

Dermatol Ther (Heidelb)
Stander S, Zeidler C, Msihid J, Makhija M, Bansal A, Wiggins S, Zahn J, Thomas RB, Bahloul D.   +8 more
europepmc   +1 more source

IgE-defined endotypes reveal distinct clinical profiles of prurigo nodularis compared with atopic dermatitis: a multicenter study in China. [PDF]

Front Allergy
Ling S, Liao Y, Chen C, Wu R, Yin M, Wei L, Chen J, Huang H, Dou X.   +8 more
europepmc   +1 more source

Experience in the management of real-world patients with chronic prurigo nodularis in a dermatology setting: results from the ECOSPIN Spanish survey-based study. [PDF]

Front Med (Lausanne)
Figueras-Nart I, Ortiz Castillo R, Serra Baldrich E.   +2 more
europepmc   +1 more source

Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials. [PDF]

An Bras Dermatol
Vieira ACP, Cruz Akabane MAC, Caletti GCG, Heffel KK, Tauana Oliveira E Silva A.   +4 more
europepmc   +1 more source

Prurigo Nodularis

The Tohoku Journal of Experimental Medicine, 1949
openaire   +2 more sources

Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross-Sectional Population-Based Analysis. [PDF]

Int J Dermatol
Valdman-Grinshpoun Y, Zaga A, Cohen AD, Schonmann Y, Czarnowicki T.   +4 more
europepmc   +1 more source

Targeting IL-31RA with nemolizumab in prurigo nodularis: a systematic review, GRADE-assessed meta-analysis, and trial sequential analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Aldamen AO, Alqahtani R, Alqahtani R, Alanazi ZM, Almutairi LH, Alghatam AS, Alamari A, Altamimi I, Yadav R, Altamimi A.   +9 more
europepmc   +1 more source

Treatment Patterns, Healthcare Utilization, and Related Costs for Prurigo Nodularis in Sweden. [PDF]

Acta Derm Venereol
Von Kobyletzki L, Metsini A, Regnell SE, Carlberg M, Svensson Å, Antelmi A.   +5 more
europepmc   +1 more source

IL31 identified as a key genetic risk factor for prurigo nodularis. [PDF]

J Allergy Clin Immunol
Patrick MT, Wu Y, Zhong X, Li Q, Julia V, Li B, Gudjonsson JE, Tsoi LC.   +7 more
europepmc   +1 more source

Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria. [PDF]

Dermatol Ther (Heidelb)
Yosipovitch G, Kim BS, Koo JY, Chen Z, Wiggins S, Zahn J, Sugerman P, Haddad EB, Cyr SL.   +8 more
europepmc   +1 more source